TXG - 10x Genomics Inc. (TXG) Q1 2024 Earnings Call Transcript
2024-04-30 23:32:01 ET
10x Genomics, Inc. (TXG)
Q1 2024 Earnings Conference Call
April 30, 2024 16:30 ET
Company Participants
Cassie Corneau - Director of Investor Relations & Strategic Finance
Serge Saxonov - Chief Executive Officer & Co-Founder
Justin McAnear - Chief Financial Officer
Conference Call Participants
Mason Carrico - Stephens, Inc.
Patrick Donnelly - Citigroup
Daniel Arias - Stifel Financial
Doug Schenkel - Wolfe Research
Dan Brennan - TD Cowen
Matt Larew - William Blair
Matthew Sykes - Goldman Sachs
Subbu Nambi - Guggenheim Partners
Michael Ryskin - Bank of America
Tejas Savant - Morgan Stanley
Luke Sergott - Barclays
Kyle Mikson - Canaccord Genuity
Presentation
Operator
Good day everyone and welcome to the 10x Genomics First Quarter 2024 Earnings Call. Today's call is being recorded. And I would like to turn the call over to Cassie Corneau, Director, Head of Investor Relations and Strategic Finance. Please go ahead.
Cassie Corneau
Thank you and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the first quarter ended March 31, 2024. If you have not received this news release or if you would like to be added to the company's distribution list, please send an e-mail to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.
Joining the call today are Serge Saxonov, our CEO and Co-Founder; and Justin McAnear, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue.
With that, I will now turn the call over to Serge.
Serge Saxonov
Thanks, Cassie and good afternoon, everyone. During today's call, I'll start with an overview of our first quarter progress and performance, highlighted by the launch of 4 major new products that we believe set a new standard for single cell and spatial biology. Next, I will discuss the exciting opportunities we have ahead across our 3 platforms and the steps we are taking to deliver on the future. Then I'll turn the call over to Justin for a more detailed look at our financials, business trends and outlook for the rest of the year....
10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript